PPT-MYELOPROLIFERATIVE DISORDERS

MPD Myeloproliferative neoplasms MPN constitute one of five categories of myeloid malignancies according to the World Health Organization WHO classification system for hematopoietic tumors. disorders. Clonal hematopoiesis (stem cell disorder). Marrow hypercellularity. Overproduction of one or more cell lines (effective hematopoiesis). Exception: myelofibrosis. Differentiation nearly normal. Kathleen Finnegan . MS MT(ASCP)SH. CM. Stony Brook University. Kathleen.finnegan@stonybrook.edu. Objectives. Describe the classification and characteristics of the MPNs. Discuss the molecular mutations associated with the MPNs and their role in the disease process.. 58% Adults Snore. 36% Complain of Insomnia. 15% note persistent Excessive Daytime Sleepiness. 3% Unusual Nocturnal Behaviors. 28% Workforce on night or rotating shifts. One in Three Individuals are Dissatisfied with Their Sleep. Marion Weeks. Jenks High School. Anxiety Disorders in general. Diagnosis occurs when overwhelming anxiety disrupts social or occupational functioning or produces significant distress.. Manifestations of anxiety. Polydactyly. Down Syndrome. Hemophelia. Progeria. Hypertrichosis. Sickle Cell Anaemia. INTRODUCTION. What is genetic diseases/disorders?. The human body is composed up of cells , each one specializing a particular function like sensing light, smelling . DSM-IV lists 10 separate personality disorders, with an average prevalence of 1-2%. Three clusters: anxious-fearful, odd-eccentric, and dramatic-impulsive. Concern:. . Categorical vs. Dimensional (DSM-V)?. Dr. Ali Khazaal Jumaa. F. .I.B.M.S (Int. Medicine), F.I.B.M.S (Hematology). . Definition. Myeloproliferative neoplasms (MPNs) are a heterogeneous group of disorders characterized by cellular proliferation of one or more hematologic cell lines.. characterised . by . overproduction of one or more myeloid cell types . via bone marrow stimulation. . Entities include;. Polycythaemia vera, (PV). Essential . thrombocythaemia . (ET). Primary . (idiopathic) . Dr. Ibrahim. A. Adam. Objectives . Discuss definition, types, . pathophysiology. , clinical features, laboratory findings, complications and treatment of essential . thrombocythsaemia. Discuss definition, . MPNs) . Clinical . Trials. Anthony J. Messina. , . MSc. , CCRP . 1,2 . Quentin E. O’Brien. , MPH. 2*. . Vasily Andrianov. , MD. 1. . Keren R. Moss. , MD. 1*. . Laura Vidal. , MD. After receiving a request from the WTC Clinical Centers of Excellence to review certain myeloid disorders in terms of their status as malignancies, 1 the WTC Health Program has determined that, 2 e g Statement of Intent and the management options available locally. Review of the Guidelines These guidelines were issued in August 2004 and will be reviewed in August 2006 or sooner CPG Secreta This synopsis has been completed by medical practitioners. It is based on a literature search at the standard of a textbook of medicine and generalist review articles. It is not intended to be a meta- . . Dr.v.shanthi. Associate professor, pathology. Sri Venkateswara institute of medical sciences. tirupathi. . POLYCYTHEMIA VERA. Neoplasm of multipotent myeloid stem cell, characterized by : . activating .